Advertisement

Ferulic acid ameliorates doxorubicin-induced cardiac toxicity in rats

  • Urmila AswarEmail author
  • Umesh Mahajan
  • Amit Kandhare
  • Manoj Aswar
Original Article
  • 6 Downloads

Abstract

Ferulic acid (FA) is a phenolic compound with potent antioxidant activity. The objective of the study was to study the protective effects of FA on doxorubicin (Dox)-induced myocardial toxicity in rats. Wistar rats received vehicle (control) or Dox (20 mg/kg, i.p.) or telmisartan (Tel; 10 mg/kg, p.o.) or ferulic acid (20 mg/kg and 40 mg/kg, p.o.) for 7 days followed by treatment with Dox (20) on the fifth day of treatment, except the control group. On day 8, electrocardiographic parameters were recorded followed by blood withdrawal and then the animals were sacrificed for histopathology. Administration of Dox showed prolonged RR, QTc interval, and QRS complex. The levels of serum CK-MB, LDH, IL-1β, and IL-6 were significantly increased (p < 0.01). Similarly, levels of Ca+2, Mg+2 ATPase, and Ca+2 ATPase and expression of ANP and BNP were significantly higher as compared to the control. In the FA-treated group, ECG was normal. The serum levels of CK-MB, LDH, IL-1β, and IL-6 were not elevated. Heart tissue Ca+2, Mg+2 ATPase, and Ca+2 ATPase did not show a statistical difference compared to the control group. The FA treatment attenuated the expression of ANP and BNP. FA (20 and 40) augmented myocardial GSH and Na+/K+ ATPase. Histopathology of the heart confirmed the cardioprotective effect of FA.

Keywords

Anti-oxidant Cardiac toxicity Doxorubicin Ferulic acid Rats 

Notes

Acknowledgements

The authors would like to acknowledge Prof. M. N. Navale, Founder, STES, and Dr. K. G. Bothara, Principal, SIOP, for providing the necessary facilities to carry out the research work.

Compliance with ethical standards

The experimental protocol was approved by the Institutional Animal Ethical Committee (IAEC) of SIOP, Pune, constituted as per the Committee for Purpose of Supervision and Control on the experimental animal CPCSEA reg. no 1139/a/07/ CPCSEA (Protocol approval no. SIOP/IAEC/2012/21B).

Conflict of interest

The authors declare that there are no conflicts of interest.

References

  1. Abdel-Wahab M, El-Mahdy M, Abd-Ellah M, Helal G, Khalifa F, Hamada F (2003) Influence of p-coumaric acid on doxorubicin-induced oxidative stress in rat’s heart. Pharmacol Res 48:461–465CrossRefGoogle Scholar
  2. Alimoradi H, Barzegar-Fallah A, Hassanzadeh G, Mohammadi-Rick S, Asadi F, Delfan B (2012) The cardioprotective effects of an antiemetic drug, tropisetron, on cardiomyopathy related to doxorubicin. Cardiovasc Toxicol 12:318–325CrossRefGoogle Scholar
  3. Al-Majed A, Gado A, Al-Shabanah O, Mansour M (2002) Alpha-lipoic acid ameliorates myocardial toxicity induced by doxorubicin. Pharmacol Res 46:499–503CrossRefGoogle Scholar
  4. Aswar U, Mahajan U, Nerurkar G, Aswar M (2013) Amelioration of cardiac hypertrophy induced by abdominal aortic banding in ferulic acid treated rats. Biomed Aging Pathol 3:209–217CrossRefGoogle Scholar
  5. Balachandar A, Malarkodi K, Varalakshmi P (2003) Protective role of D La-lipoic acid against adriamycin-induced cardiac lipid peroxidation. Hum Exp Toxicol 22:249–254CrossRefGoogle Scholar
  6. Bujak M, Frangogiannis N (2009) The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp 57:165–176CrossRefGoogle Scholar
  7. Buyukokuroglu M, Taysi S, Buyukavci M, Bakan E (2004) Prevention of acute adriamycin cardiotoxicity by dantrolene in rats. Hum Exp Toxicol 23:251–256CrossRefGoogle Scholar
  8. Chen M, Yang S, Chou C, Yang K, Wu C, Cheng Y (2010) The chondroprotective effects of ferulic acid on hydrogen peroxide-stimulated chondrocytes: inhibition of hydrogen peroxide-induced pro-inflammatory cytokines and metalloproteinase gene expression at the mRNA level. Inflamm Res 59:587–595CrossRefGoogle Scholar
  9. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R (2008) Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 198(1):22–28CrossRefGoogle Scholar
  10. de Oliveira Silva E, Batista R (2017) Ferulic acid and naturally occurring compounds bearing a feruloyl moiety: a review on their structures, occurrence, and potential health benefits. Compr Rev Food Sci Food Saf 16(4):580–616CrossRefGoogle Scholar
  11. Dodd D, Atkinson J, Olson R, Buck S, Cusack B, Fleischer S (1993) Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J Clin Invest 91:1697–1705CrossRefGoogle Scholar
  12. Fadillioglu E, Oztas E, Erdogan H, Yagmurca M, Sogut S, Ucar M (2004) Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats. J Appl Toxicol 24:47–52CrossRefGoogle Scholar
  13. Gao S, Long C, Wang R, Wang H (2009) KATP activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc Res 83:444–456CrossRefGoogle Scholar
  14. Hadi N, Yousif G, Al-Amran HN, Mohammad B, Ali S (2012) Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response. BMC Cardiovasc Disord 12(1):63–70CrossRefGoogle Scholar
  15. Henninger C, Huelsenbeck J, Huelsenbeck S, Grosch S, Schad A, Lackner K (2012) The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity. Toxicol Appl Pharmacol 261:66–73CrossRefGoogle Scholar
  16. Hjerten S, Pan H (1983) Purification and characterization of two forms of a low-affinity Ca2+-ATPase from erythrocyte membranes. Biochim Biophys Acta Biomembr 728:281–288CrossRefGoogle Scholar
  17. Hortobagyi G (1997) Anthracyclines in the treatment of cancer. Drugs 54(4):1–7CrossRefGoogle Scholar
  18. Hou Z, Yang J, Zhao R, Yuan J (2004) Ferulic acid inhibits vascular smooth muscle cell proliferation induced by angiotensin II. Eur J Pharmacol 499:85–90CrossRefGoogle Scholar
  19. Iqbal M, Dubey K, Anwer T, Ashish A, Pillai K (2008) Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 60(3):382–390Google Scholar
  20. Kalivendi S, Konorev E, Cunningham S, Vanamala S, Kaji E, Joseph J (2005) Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium. Biochem J 389:527–539CrossRefGoogle Scholar
  21. Kania G, Blyszczuk P, Eriksson U (2009) Mechanisms of cardiac fibrosis in inflammatory heart disease. Trends Cardiovasc Med 19:247–252CrossRefGoogle Scholar
  22. Kim DH, Landry IIIAB, Lee YS, Katz AM (1989) Doxorubicin-induced calcium release from cardiac sarcoplasmic reticulum vesicles. J Mol Cell Cardiol 21(5):433–436CrossRefGoogle Scholar
  23. Kobayashi N, Ohno T, Yoshida K, Fukushima H, Mamada Y, Nomura M, Hirata H, Machida Y, Shinoda M, Suzuki N, Matsuoka H (2008) Cardioprotective mechanism of telmisartan via PPAR-γ-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens 21(5):576–581CrossRefGoogle Scholar
  24. Kojima R, Toyama Y, Ohnishi S (1994) Protective effects of an aged garlic extract on doxorubicin-induced cardiotoxicity in the mouse. Nutr Cancer 22(2):163–173CrossRefGoogle Scholar
  25. Ludke A, Sharma A, Singal P (2010) Vitamin C modulates doxorubicin-induced cardiotoxicity by reducing oxidative stress and p53 activation. Can J Cardiol 26:71–72dCrossRefGoogle Scholar
  26. Ludke L, Al-Shudiefat A, Dhingra S, Jassal D, Singal P (2009) A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity. Can J Physiol Pharm 87(10):756–763Google Scholar
  27. Mancuso C, Santangelo R (2014) Ferulic acid: pharmacological and toxicological aspects. Food Chem Toxicol 65:185–195CrossRefGoogle Scholar
  28. Maurya D, Devasagayam TPA (2010) Antioxidant and prooxidant nature of hydroxycinnamic acid derivatives ferulic and caffeic acids. Food Chem Toxicol 48(12):3369–3373Google Scholar
  29. Mohamad R, El-Bastawesy A, Zekry Z, Al-Mehdar H, Al-said M, Aly S (2009) The role of Curcuma longa against doxorubicin (adriamycin)-induced toxicity in rats. J Med Food 12:394–402CrossRefGoogle Scholar
  30. Moron M, Depierre J, Mannervik B (1979) Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta Gen Subj 582:67–78CrossRefGoogle Scholar
  31. Nagi M, Almakki H (2009) Thymoquinone supplementation induces quinone reductase and glutathione transferase in mice liver: possible role in protection against chemical carcinogenesis and toxicity. Phytother Res 23:1295–1298CrossRefGoogle Scholar
  32. Nousiainen T, Jantunen E, Vanninen E, Remes J, Vuolteenaho O, Hartikainen J (1999) Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin’s lymphoma. Eur J Haematol 62:135–141CrossRefGoogle Scholar
  33. Octavia Y, Tocchetti C, Gabrielson K, Janssens S, Crijns H, Moens A (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52:1213–1225CrossRefGoogle Scholar
  34. Ohnishi T, Suzuki T, Suzuki Y, Ozawa K (1982) A comparative study of plasma membrane Mg2+-ATPase activities in normal, regenerating and malignant cells. Biochim Biophys Acta Biomembr 684:67–74CrossRefGoogle Scholar
  35. Oktem G, Uysal A, Oral O, Sezer E, Olukman M, Erol A (2012) Resveratrol attenuates doxorubicin-induced cellular damage by modulating nitric oxide and apoptosis. Exp Toxicol Pathol 64:471–479CrossRefGoogle Scholar
  36. Piazzon A, Vrhovsek U, Masuero D, Mattivi F, Mandoj F, Nardini M (2012) Antioxidant activity of phenolic acids and their metabolites: synthesis and antioxidant properties of the sulfate derivatives of ferulic and caffeic acids and of the acyl glucuronide of ferulic acid. J Agric Food Chem 60:12312–12323CrossRefGoogle Scholar
  37. Potemski P, Polakowski P, Wiktorowska-Owczarek A, Owczarek J, Pluzanska A, Orszulak-Michalak D (2006) Amifostine improves hemodynamic parameters in doxorubicin-pretreated rabbits. Pharmacol Rep 58:966–972Google Scholar
  38. Pugazhendhi A, Edison T, Velmurugan B, Jacob J, Karuppusamy I (2018) Toxicity of doxorubicin (dox) to different experimental organ systems. Life Sci 200:26–30CrossRefGoogle Scholar
  39. Radwan R, Shaban E, Kenawy S, Salem H (2012) Protection by low-dose γ radiation on doxorubicin-induced nephropathy in rats pretreated with curcumin, green tea, garlic or l-carnitine. Bull Fac Pharm Cairo Univ 50:133–140CrossRefGoogle Scholar
  40. Rossi F, Filippelli W, Russo S, Filippelli A, Berrino L (1994) Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances. Pharmacol Toxicol 75:99–107CrossRefGoogle Scholar
  41. Sampath P, Vijayaragavan K (2008) Ameliorative prospective of alpha-mangostin, a xanthone derivative from Garcinia mangostana against β-adrenergic cathecolamine-induced myocardial toxicity and anomalous cardiac TNF-α and COX-2 expressions in rats. Exp Toxicol Pathol 60:357–364CrossRefGoogle Scholar
  42. Shadle S, Bammel B, Cusack B, Knighton R, Olson S, Mushlin P (2000) Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Biochem Pharmacol 60:1435–1444CrossRefGoogle Scholar
  43. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900–905CrossRefGoogle Scholar
  44. Singal P, Panagia V (1984) Direct effects of adriamycin on the rat heart sarcolemma. Res Commun Chem Pathol Pharmacol 43:67–77Google Scholar
  45. Srinivasan M, Sudheer A, Menon V (2007) Ferulic acid: therapeutic potential through its antioxidant property. J Clin Biochem Nutr 40:92–110CrossRefGoogle Scholar
  46. Tacar O, Sriamornsak P, Dass CR (2013) Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 65(2):157–170CrossRefGoogle Scholar
  47. Trombino S, Cassano R, Bloise E, Muzzalupo R, Tavano L, Picci N (2009) Synthesis and antioxidant activity evaluation of a novel cellulose hydrogel containing trans-ferulic acid. Carbohydr Polym 75:184–188CrossRefGoogle Scholar
  48. Vallejo J, Salazar L, Marcelo G (2017) Oxidative stress modulation and ROS-mediated toxicity in cancer: a review on in vitro models for plant-derived compounds. Oxid Med Cell Longev 1–9Google Scholar
  49. Yu J, Wang C, Kong Q, Wu X, Lu J, Chen X (2018) Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products. Phytomed 40:125–139CrossRefGoogle Scholar
  50. Zhang S, Liu X, Bawa-Khalfe T, Lu L, Lyu Y, Liu L (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18:1639–1642CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of PharmacologyPoona College of Pharmacy, Bharati Vidyapeeth Deemed UniversityPuneIndia
  2. 2.Department of PharmacologySinhgad Institute of PharmacyPuneIndia

Personalised recommendations